ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)

Author:

Jariwala Pankaj,Jadhav Kartik,Punjani Arshad,Boorugu Harikishan,Mari Ajay Reddy

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology foundation/American heart association task force on practice guidelines;Yancy;J Am Coll Cardiol,2013

2. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer;Yancy,2017

3. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurrayJJV;N Engl J Med,2019

4. SS. DAPA- HF Committees and Investigators. A trial to evaluate the effect of the sodium– glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA- HF);McMurray;Eur J Heart Fail,2019

5. Consensus and development of document for management of stabilized acute decompensated heart failure with reduced ejection fraction in India;Kaul,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3